| Cover Page | 12 Months Ended |
| Dec. 31, 2022 shares |
| Document Information [Line Items] | |
| Document Type | 20-F/A |
| Amendment Flag | true |
| Document Period End Date | Dec. 31, 2022 |
| Document Fiscal Year Focus | 2022 |
| Document Fiscal Period Focus | FY |
| Entity Registrant Name | GSK plc |
| Entity Central Index Key | 0001131399 |
| Current Fiscal Year End Date | --12-31 |
| Entity Filer Category | Large Accelerated Filer |
| Document Annual Report | true |
| Document Transition Report | false |
| Entity File Number | 1-15170 |
| Document Shell Company Report | false |
| Entity Address, Address Line One | 980 Great West Road, Brentford |
| Entity Address, City or Town | Middlesex |
| Entity Address, Country | GB |
| Entity Incorporation, State or Country Code | X0 |
| Entity Address, Postal Zip Code | TW8 9GS |
| Entity Emerging Growth Company | false |
| Entity Shell Company | false |
| Entity Common Stock, Shares Outstanding | 4,311,343,341 |
| Entity Well-known Seasoned Issuer | No |
| Entity Voluntary Filers | No |
| Entity Current Reporting Status | Yes |
| Entity Interactive Data Current | Yes |
| Document Accounting Standard | International Financial Reporting Standards |
| ICFR Auditor Attestation Flag | true |
| Document Registration Statement | false |
| Auditor Name | Deloitte LLP |
| Auditor Firm ID | 1147 |
| Auditor Location | London, United Kingdom |
| Amendment Description | This Amendment No. 1 to Form 20-F (“Amendment No. 1”) amends our Annual Report on Form 20-F for the fiscal year ended December 31, 2022 (the “Form 20-F”), which was originally filed with the U.S. Securities and Exchange Commission on March 10, 2023 (the “Original Filing Date”). This Amendment No. 1 is being filed at the request of our auditor to (a) include the inadvertently omitted (i) conformed signature of Deloitte LLP, our Independent Registered Public Accounting Firm, and (ii) statement containing the year the auditor began serving consecutively as GSK plc’s auditor, in each case in the “Report of Independent Registered Public Accounting Firm” (the “Audit Report”) on p. 83 of the Form 20-F, and to (b) change the date in the second paragraph on p. 77 of the Form 20-F from “10 March 2022” to “10 March 2023.” There are no other changes to the Audit Report or to the Form 20-F. The consolidated financial statements and notes to the consolidated financial statements remain the same as the previously filed Form 20-F.In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment No. 1 includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, dated as of the filing date of this Amendment No. 1. Except for the changes expressly described above, this Amendment No. 1 continues to present information as at the Original Filing Date and does not amend, supplement or update any information contained in the Form 20-F to give effect to any subsequent events. The filing of this Amendment No. 1, and the inclusion of newly executed certifications, should not be understood to mean that any other statements or disclosure contained in the Form 20-F are true and complete as of any date subsequent to the Original Filing Date, except as expressly noted above. Accordingly, this Amendment No. 1 should be read in conjunction with the Form 20-F. |
| Business Contact [Member] | |
| Document Information [Line Items] | |
| Entity Address, Address Line One | 980 Great West Road |
| Entity Address, City or Town | Brentford |
| Entity Address, Country | GB |
| Entity Address, Postal Zip Code | TW8 9GS |
| Contact Personnel Name | Victoria Whyte |
| Contact Personnel Email Address | company.secretary@gsk.com |
| City Area Code | 44 20 |
| Local Phone Number | 8047 5000 |
| American Depositary Shares [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK |
| Title of 12(b) Security | American Depositary Shares |
| Security Exchange Name | NYSE |
| 0.534% Notes due 2023 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/23C |
| Title of 12(b) Security | 0.534% Notes due 2023 |
| Security Exchange Name | NYSE |
| 3.000% Notes due 2024 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/24 |
| Title of 12(b) Security | 3.000% Notes due 2024 |
| Security Exchange Name | NYSE |
| 3.625% Notes due 2025 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/25 |
| Title of 12(b) Security | 3.625% Notes due 2025 |
| Security Exchange Name | NYSE |
| 3.875% Notes due 2028 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/28 |
| Title of 12(b) Security | 3.875% Notes due 2028 |
| Security Exchange Name | NYSE |
| 3.375% Notes due 2029 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/29 |
| Title of 12(b) Security | 3.375% Notes due 2029 |
| Security Exchange Name | NYSE |
| 6.375% Notes due 2038 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/38 |
| Title of 12(b) Security | 6.375% Notes due 2038 |
| Security Exchange Name | NYSE |
| 4.200% Notes due 2043 [Member] | |
| Document Information [Line Items] | |
| Trading Symbol | GSK/43 |
| Title of 12(b) Security | 4.200% Notes due 2043 |
| Security Exchange Name | NYSE |
